William Blair & Company’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

William Blair & Company’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$278K	Buy	3,097 +2,097	+210%	+$173K	﹤0.01%	1453
2026 Q1	$79.2K	Hold	1,000	–	–	﹤0.01%	1633
2025 Q4	$82.2K	Hold	1,000	–	–	﹤0.01%	1599
2025 Q3	$69.9K	Buy	1,000 +600	+150%	+$40.5K	﹤0.01%	1601
2025 Q2	$25.6K	Hold	400	–	–	﹤0.01%	1660
2025 Q1	$25.4K	Hold	400	–	–	﹤0.01%	1645
2024 Q4	$26.6K	Hold	400	–	–	﹤0.01%	1670
2024 Q3	$27.9K	Hold	400	–	–	﹤0.01%	1683
2024 Q2	$25.9K	Hold	400	–	–	﹤0.01%	1667
2024 Q1	$25.9K	Hold	400	–	–	﹤0.01%	1659
2023 Q4	$26.3K	Hold	400	–	–	﹤0.01%	1648
2023 Q3	$22.8K	Hold	400	–	–	﹤0.01%	1672
2023 Q2	$24.5K	Hold	400	–	–	﹤0.01%	1676
2023 Q1	$25.1K	Hold	400	–	–	﹤0.01%	1666
2022 Q4	$25.4K	Hold	400	–	–	﹤0.01%	1657
2022 Q3	$24K	Hold	400	–	–	﹤0.01%	1681
2022 Q2	$23K	Hold	400	–	–	﹤0.01%	1712
2022 Q1	$25K	Hold	400	–	–	﹤0.01%	1774
2021 Q4	$28K	Hold	400	–	–	﹤0.01%	1825
2021 Q3	$30K	Hold	400	–	–	﹤0.01%	1737
2021 Q2	$31K	Hold	400	–	–	﹤0.01%	1744
2021 Q1	$30K	Hold	400	–	–	﹤0.01%	1719
2020 Q4	$28K	Hold	400	–	–	﹤0.01%	1676
2020 Q3	$23K	Hold	400	–	–	﹤0.01%	1571
2020 Q2	$23K	Hold	400	–	–	﹤0.01%	1525
2020 Q1	$19K	Hold	400	–	–	﹤0.01%	1499
2019 Q4	$22K	Hold	400	–	–	﹤0.01%	1575
2019 Q3	$19K	Hold	400	–	–	﹤0.01%	1553
2019 Q2	$21K	Hold	400	–	–	﹤0.01%	1581
2019 Q1	$22K	Hold	400	–	–	﹤0.01%	1554
2018 Q4	$19K	Hold	400	–	–	﹤0.01%	1497
2018 Q3	$24K	Hold	400	–	–	﹤0.01%	1515
2018 Q2	$22K	Hold	400	–	–	﹤0.01%	1491
2018 Q1	$20K	Buy	+400	New	+$20.4K	﹤0.01%	1421

Other funds holding PBE

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UCFA

United Capital Financial Advisors Irving, Texas $18.2B AUM 22.02% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

GKWIM

Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.75B AUM 28.61% 1-Year Est. Return

Cetera Investment Advisers Schaumburg, Illinois $110B AUM 26.29% 1-Year Est. Return

YIA

YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return

William Blair & Company's PBE Position: Q2 2026 in Review

William Blair & Company increased its Invesco Biotechnology & Genome ETF (PBE) stake by 210% in Q2 2026, buying an estimated $173K and bringing the position to 3,097 shares worth $278K. The position accounts for ﹤0.01% of the portfolio, ranked #1453.

William Blair & Company first reported a position in PBE in Q1 2018 and has held it in 34 quarters since. 104 funds tracked by Wall St. Rank hold PBE as of Q2 2026.

William Blair & Company held 3,097 shares of Invesco Biotechnology & Genome ETF worth $278K as of Q2 2026.
William Blair & Company bought 2,097 Invesco Biotechnology & Genome ETF shares in Q2 2026, an estimated $173K.
Invesco Biotechnology & Genome ETF made up ﹤0.01% of William Blair & Company's portfolio in Q2 2026, its #1453 holding.
William Blair & Company first reported a position in Invesco Biotechnology & Genome ETF in Q1 2018 and has held it in 34 quarters since.
104 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q2 2026.

Based on William Blair & Company's 13F filing for Q2 2026, filed 11 Aug 2026.